Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 13Lung Neoplasms 12Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroblastoma 4Glioblastoma 4Colorectal Neoplasms 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Disease 3Carcinoma, Hepatocellular 3Carcinoma 3Ureteral Neoplasms 2Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Mantle-Cell 2

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pleuropulmonary blastoma × Magnetic Resonance Spectroscopy × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡